Literature DB >> 28664468

Tumor Treating Fields in Neuro-Oncological Practice.

Maciej M Mrugala1,2,3,4, Jacob Ruzevick5, Piotr Zlomanczuk6, Rimas V Lukas7.   

Abstract

Electric fields are known to produce biological effects. Depending on specific frequency, they can stimulate healing, directly damage tissues, or produce anti-mitotic activity. Frequencies of 100-300 KHz have been shown to disrupt mitosis and lead to cellular death. Growth of cancer cell lines, both in vitro and in vivo, was shown to be inhibited by application of the electric fields. In the clinical setting, electric fields are available for treatment of brain tumors, specifically glioblastoma (GBM), through a portable device producing so-called tumor treating fields (TTF). Clinical trials conducted in patients with recurrent and newly diagnosed GBM indicated that this novel treatment modality is active and associated with minimal toxicity. This manuscript will review the available evidence supporting the use of TTF in neuro-oncologic practice.

Entities:  

Keywords:  Bevacizumab; Glioblastoma; NovoTTF; Tumor treating fields

Mesh:

Year:  2017        PMID: 28664468     DOI: 10.1007/s11912-017-0611-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  24 in total

1.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

2.  Economics of Malignant Gliomas: A Critical Review.

Authors:  Jeffrey J Raizer; Karen A Fitzner; Daniel I Jacobs; Charles L Bennett; Dustin B Liebling; Thanh Ha Luu; Steven M Trifilio; Sean A Grimm; Matthew J Fisher; Meraaj S Haleem; Paul S Ray; Judith M McKoy; Rebecca DeBoer; Katrina-Marie E Tulas; Mohammed Deeb; June M McKoy
Journal:  J Oncol Pract       Date:  2014-12-02       Impact factor: 3.840

3.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

4.  A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer.

Authors:  Miklos Pless; Cornelia Droege; Roger von Moos; Marc Salzberg; Daniel Betticher
Journal:  Lung Cancer       Date:  2013-07-23       Impact factor: 5.705

5.  Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy.

Authors:  Andrew A Kanner; Eric T Wong; John L Villano; Zvi Ram
Journal:  Semin Oncol       Date:  2014-09-16       Impact factor: 4.929

6.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

7.  Disruption of cancer cell replication by alternating electric fields.

Authors:  Eilon D Kirson; Zoya Gurvich; Rosa Schneiderman; Erez Dekel; Aviran Itzhaki; Yoram Wasserman; Rachel Schatzberger; Yoram Palti
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

8.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

9.  Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields).

Authors:  Eilon D Kirson; Rosa S Schneiderman; Vladimír Dbalý; Frantisek Tovarys; Josef Vymazal; Aviran Itzhaki; Daniel Mordechovich; Zoya Gurvich; Esther Shmueli; Dorit Goldsher; Yoram Wasserman; Yoram Palti
Journal:  BMC Med Phys       Date:  2009-01-08

Review 10.  An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma.

Authors:  Kenneth D Swanson; Edwin Lok; Eric T Wong
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

View more
  7 in total

Review 1.  Newly Diagnosed Glioblastoma: A Review on Clinical Management.

Authors:  Rimas V Lukas; Derek A Wainwright; Erik Ladomersky; Sean Sachdev; Adam M Sonabend; Roger Stupp
Journal:  Oncology (Williston Park)       Date:  2019-03-13       Impact factor: 2.990

Review 2.  Immunotherapy Against Gliomas: is the Breakthrough Near?

Authors:  Rimas V Lukas; Derek A Wainwright; Craig M Horbinski; Fabio M Iwamoto; Adam M Sonabend
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

Review 3.  Recurrent glioma clinical trial, CheckMate-143: the game is not over yet.

Authors:  Anna C Filley; Mario Henriquez; Mahua Dey
Journal:  Oncotarget       Date:  2017-10-06

4.  BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma.

Authors:  Rimas V Lukas; Ryan T Merrell
Journal:  CNS Oncol       Date:  2018-04-30

5.  Reduction of intratumoral brain perfusion by noninvasive transcranial electrical stimulation.

Authors:  G Sprugnoli; L Monti; L Lippa; F Neri; L Mencarelli; G Ruffini; R Salvador; G Oliveri; B Batani; D Momi; A Cerase; A Pascual-Leone; A Rossi; S Rossi; E Santarnecchi
Journal:  Sci Adv       Date:  2019-08-14       Impact factor: 14.136

6.  Comparison of the Functional State and Motor Skills of Patients after Cerebral Hemisphere, Ventricular System, and Cerebellopontine Angle Tumor Surgery.

Authors:  Stanisław Krajewski; Jacek Furtak; Monika Zawadka-Kunikowska; Michał Kachelski; Marcin Birski; Marek Harat
Journal:  Int J Environ Res Public Health       Date:  2022-02-17       Impact factor: 3.390

Review 7.  Imaging of GBM in the Age of Molecular Markers and MRI Guided Adaptive Radiation Therapy.

Authors:  Salah Dajani; Virginia B Hill; John A Kalapurakal; Craig M Horbinski; Eric G Nesbit; Sean Sachdev; Amulya Yalamanchili; Tarita O Thomas
Journal:  J Clin Med       Date:  2022-10-10       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.